| Citation: | Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of China Research Hospital Association. The Guideline for Neoadjuvant Therapy of Pancreatic Cancer in China (2020 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 547-558. doi: 10.3969/j.issn.1674-9081.2020.05.010
|
| [1] | Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. doi: 10.1016/j.jclinepi.2010.07.015 |
| [2] | Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians?[J]. BMJ, 2008, 336: 995-998. doi: 10.1136/bmj.39490.551019.BE |
| [3] | Guyatt GH, Oxman AD, Sultan S, et al. GRADE guide-lines: 9. Rating up the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 1311-1316. doi: 10.1016/j.jclinepi.2011.06.004 |
| [4] | Andrews J, Guyatt G, Oxman AD, et al. GRADE guide-lines: 14. Going from evidence to recommendations: the significance and presentation of recommendations[J]. J Clin Epidemiol, 2013, 66: 719-725. doi: 10.1016/j.jclinepi.2012.03.013 |
| [5] | Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength[J]. J Clin Epidemiol, 2013, 66: 726-735. doi: 10.1016/j.jclinepi.2013.02.003 |
| [6] | de Geus SW, Eskander MF, Bliss LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis[J]. Surgery, 2017, 161: 592-601. doi: 10.1016/j.surg.2016.08.040 |
| [7] | Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis[J]. J Clin Oncol, 2017, 35: 515-522. http://www.ncbi.nlm.nih.gov/pubmed/27621388 |
| [8] | Lee YS, Lee JC, Yang SY, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis[J]. Sci Rep, 2019, 9: 15662. doi: 10.1038/s41598-019-52167-9 |
| [9] | Motoi F, Unno M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma[J]. Jpn J Clin Oncol, 2020, 50:483-489. doi: 10.1093/jjco/hyaa018 |
| [10] | Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)[J]. Jpn J Clin Oncol, 2019, 49: 190-194. doi: 10.1093/jjco/hyy190 |
| [11] | Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase Ⅲ PREOPANC Trial[J]. J Clin Oncol, 2020, 38:1763-1773. doi: 10.1200/JCO.19.02274 |
| [12] | Jang JY, Han Y, Lee H, et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial[J]. Ann Surg, 2018, 268: 215-222. doi: 10.1097/SLA.0000000000002705 |
| [13] | Barnes CA, Krepline AN, Aldakkak M, et al. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?[J]. J Gastrointest Surg, 2017, 21: 1793-1803. doi: 10.1007/s11605-017-3544-5 |
| [14] | Hackert T, Sachsenmaier M, Hinz U, et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients[J]. Ann Surg, 2016, 264: 457-463. doi: 10.1097/SLA.0000000000001850 |
| [15] | Gemenetzis G, Groot VP, Blair AB, et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection[J]. Ann Surg, 2019, 270: 340-347. doi: 10.1097/SLA.0000000000002753 |
| [16] | Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study[J]. Lancet Gastroenterol Hepatol, 2020, 5: 285-294. doi: 10.1016/S2468-1253(19)30327-9 |
| [17] | Okasha HH, Naga MI, Esmat S, et al. Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Percutaneous Ultrasound-Guided Fine Needle Aspiration in Diagnosis of Focal Pancreatic Masses[J]. Endosc Ultrasound, 2013, 2: 190-193. doi: 10.4103/2303-9027.121239 |
| [18] | Lutz MP, Zalcberg JR, Ducreux M, et al. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer[J]. Eur J Cancer, 2017, 79: 41-49. doi: 10.1016/j.ejca.2017.03.022 |
| [19] | Tsuboi T, Sasaki T, Serikawa M, et al. Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery[J]. Gastroenterol Res Pract, 2016, 2016: 7968201. http://pubmedcentralcanada.ca/pmcc/articles/PMC4736763/ |
| [20] | Kuwatani M, Nakamura T, Hayashi T, et al. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents[J]. Gut Liver, 2020, 14: 269-273. doi: 10.5009/gnl18573 |
| [21] | Nakamura K, Sho M, Akahori T, et al. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer[J]. World J Surg, 2019, 43: 642-648. doi: 10.1007/s00268-018-4820-6 |
| [22] | Gardner TB, Spangler CC, Byanova KL, et al. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial[J]. Gastrointest Endosc, 2016, 84: 460-466. doi: 10.1016/j.gie.2016.02.047 |
| [23] | Seo DW, Sherman S, Dua KS, et al. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial[J]. Gastrointest Endosc, 2019, 90: 602-612.e604. doi: 10.1016/j.gie.2019.06.032 |
| [24] | Uemura K, Murakami Y, Satoi S, et al. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study[J]. Ann Surg Oncol, 2015, 22: S1238-1246. doi: 10.1245/s10434-015-4618-9 |
| [25] | Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3: 413-423. doi: 10.1016/S2468-1253(18)30081-5 |
| [26] | Groot VP, Gemenetzis G, Blair AB, et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma[J]. Ann Surg, 2019, 269: 1154-1162. doi: 10.1097/SLA.0000000000002734 |
| [27] | Marchegiani G, Andrianello S, Malleo G, et al. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM[J]. Ann Surg, 2017, 266: 142-148. doi: 10.1097/SLA.0000000000001837 |
| [28] | Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study[J]. J Am Coll Surg, 2016, 223: 52-65. doi: 10.1016/j.jamcollsurg.2016.02.009 |
| [29] | Liu L, Xu HX, Wang WQ, et al. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer[J]. Int J Cancer, 2015, 136: 2216-2227. doi: 10.1002/ijc.29242 |
| [30] | Vyas SJ, Puri YS, John BJ, et al. Radiological tumor density and lymph node size correlate with survival in resectable adenocarcinoma of the pancreatic head: A retrospective cohort study[J]. J Cancer Res Ther, 2016, 12: 417-421. doi: 10.4103/0973-1482.171358 |
| [31] | Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets[J]. J Gastrointest Surg, 2015, 19: 1802-1812. doi: 10.1007/s11605-015-2890-4 |
| [32] | Tajima H, Kitagawa H, Tsukada T, et al. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer[J]. Mol Clin Oncol, 2013, 1: 768-772. doi: 10.3892/mco.2013.133 |
| [33] | Motoi F, Satoi S, Honda G, et al. A single-arm, phase Ⅱ trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcino-ma: PREP-01 study[J]. J Gastroenterol, 2019, 54: 194-203. doi: 10.1007/s00535-018-1506-7 |
| [34] | Cerullo M, Gani F, Chen SY, et al. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer[J]. Ann Surg, 2018, 267: 544-551. doi: 10.1097/SLA.0000000000002069 |
| [35] | Ettrich TJ, Berger AW, Perkhofer L, et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitab-ine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase Ⅱ study of the AIO pancreatic cancer group[J]. BMC Cancer, 2018, 18: 1298. doi: 10.1186/s12885-018-5183-y |
| [36] | Tachezy M, Gebauer F, Petersen C, et al. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasi-zed pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase Ⅲ study (NCT01900327, DRKS00003893, ISRCTN82191749)[J]. BMC Cancer, 2014, 14: 411. doi: 10.1186/1471-2407-14-411 |
| [37] | Okano K, Suto H, Oshima M, et al. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma[J]. Ann Surg Oncol, 2017, 24: 2777-2784. doi: 10.1245/s10434-017-5921-4 |
| [38] | Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma[J]. J Natl Cancer Inst, 2015, 107: djv132. doi: 10.1093/jnci/djv132. |
| [39] | Tsai S, Christians KK, George B, et al. A Phase Ⅱ Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma[J]. Ann Surg, 2018, 268: 610-619. doi: 10.1097/SLA.0000000000002957 |
| [40] | Mellon EA, Strom TJ, Hoffe SE, et al. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer[J]. J Gastrointest Oncol, 2016, 7: 547-555. doi: 10.21037/jgo.2016.03.15 |
| [41] | Chuong MD, Frakes JM, Figura N, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer[J]. J Gastrointest Oncol, 2016, 7: 221-227. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5ddb4304-2524-49ec-a677-b3e46055f722 |
| [42] | Masui T, DoiR, Kawaguchi Y, et al. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors[J]. Surg Today, 2016, 46: 1282-1289. doi: 10.1007/s00595-016-1310-z |
| [43] | Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261: 12-17. doi: 10.1097/SLA.0000000000000867 |
| [44] | Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas[J]. Ann Surg Oncol, 2015, 22: 1153-1159. doi: 10.1245/s10434-014-4225-1 |
| [45] | Takeda Y, Nakamori S, Eguchi H, et al. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma[J]. Jpn J Clin Oncol, 2014, 44: 1172-1180. doi: 10.1093/jjco/hyu143 |
| [46] | Okada KI, Hirono S, Kawai M, et al. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer[J]. Anticancer Res, 2017, 37: 853-858. doi: 10.21873/anticanres.11389 |
| [47] | Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial[J]. JAMA Oncol, 2018, 4: 963-969. doi: 10.1001/jamaoncol.2018.0329 |
| [48] | Peterson SL, Husnain M, Pollack T, et al. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX[J]. Anticancer Res, 2018, 38: 4035-4039. doi: 10.21873/anticanres.12692 |
| [49] | Dhir M, Zenati MS, Hamad A, et al. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma[J]. Ann Surg Oncol, 2018, 25: 1896-1903. doi: 10.1245/s10434-018-6512-8 |
| [50] | Macedo FI, Ryon E, Maithel SK, et al. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer[J]. Ann Surg, 2019, 270: 400-413. doi: 10.1097/SLA.0000000000003468 |
| [51] | Nagakawa Y, Hosokawa Y, Nakayama H, et al. A phase Ⅱ trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement[J]. Cancer Chemother Pharmacol, 2017, 79: 951-957. doi: 10.1007/s00280-017-3288-7 |
| [52] | Tienhoven GV, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase Ⅲ trial[J]. 2018, 36: LBA4002. doi: 10.1200/JCO.2018.36.18_suppl.LBA4002. |
| [53] | Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery[J]. Ann Surg Oncol, 2019, 26: 1629-1636. doi: 10.1245/s10434-018-07131-8 |
| [54] | Cloyd JM, Chen HC, Wang X, et al. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis[J]. Pancreas, 2019, 48: 216-222. doi: 10.1097/MPA.0000000000001231 |
| [55] | Truty MJ, Kendrick ML, Nagorney DM, et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer[J]. Ann Surg, 2019. doi: 10.1097/SLA.0000000000003284. |
| [56] | Passardi A, Scarpi E, Neri E, et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase Ⅱ Study[J]. Cancers (Basel), 2019, 11:663. doi: 10.3390/cancers11050663 |
| [57] | Li X, Guo CX, Li QH, et al. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Out-comes of Locally Advanced Pancreatic Cancer in Chinese Population[J]. Oncologist, 2019, 24: 301-e393. doi: 10.1634/theoncologist.2018-0696 |
| [58] | Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial[J]. JAMA Oncol, 2019, 5: 1020-1027. doi: 10.1001/jamaoncol.2019.0892 |
| [59] | Dholakia AS, Hacker-Prietz A, Wild AT, et al. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships[J]. J Radiat Oncol, 2013, 2: 413-425. doi: 10.1007/s13566-013-0115-6 |
| [60] | Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma[J]. Eur Radiol, 2017, 27: 3104-3116. doi: 10.1007/s00330-016-4632-8 |
| [61] | Barreto SG, Loveday B, Windsor JA, et al. Detecting tumour response and predicting resectability after neoadju-vant therapy for borderline resectable and locally advanced pancreatic cancer[J]. ANZ J Surg, 2019, 89: 481-487. doi: 10.1111/ans.14764 |
| [62] | Michelakos T, Pergolini I, Castillo CF, et al. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX[J]. Ann Surg, 2019, 269: 733-740. doi: 10.1097/SLA.0000000000002600 |
| [63] | Aoki S, Motoi F, Murakami Y, et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients[J]. BMC Cancer, 2019, 19: 252. doi: 10.1186/s12885-019-5460-4 |
| [64] | van Veldhuisen E, Vogel JA, Klompmaker S, et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy[J]. HPB (Oxford), 2018, 20: 605-611. doi: 10.1016/j.hpb.2018.01.001 |
| [65] | Yokose T, Kitago M, Matsusaka Y, et al. Usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma[J]. Cancer Med, 2020, 9:4059-4068. doi: 10.1002/cam4.3044 |
| [66] | Groot VP, Mosier S, Javed AA, et al. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer[J]. Clin Cancer Res, 2019, 25: 4973-4984. doi: 10.1158/1078-0432.CCR-19-0197 |
| [67] | Tee MC, Krajewski AC, Groeschl RT, et al. Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection[J]. J Am Coll Surg, 2018, 227: 255-269. doi: 10.1016/j.jamcollsurg.2018.05.001 |
| [68] | Del Chiaro M, Rangelova E, Halimi A, et al. Pancreatec-tomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer[J]. HPB (Oxford), 2019, 21: 219-225. doi: 10.1016/j.hpb.2018.07.017 |
| [69] | Selvaggi F, Mascetta G, Daskalaki D, et al. Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospec-tive comparative study[J]. Langenbecks Arch Surg, 2014, 399: 659-665. doi: 10.1007/s00423-014-1194-6 |
| [70] | Wang W, He Y, Wu L, et al. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis[J]. Pancreatology, 2019, 19: 1074-1080. doi: 10.1016/j.pan.2019.10.003 |
| [71] | Tashiro M, Yamada S, Sonohara F, et al. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer[J]. Ann Surg Oncol, 2018, 25: 3365-3371. doi: 10.1245/s10434-018-6699-8 |
| [72] | Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications[J]. Ann Surg Oncol, 2018, 25: 626-637. http://europepmc.org/abstract/MED/29214453 |
| [73] | Hank T, Sandini M, Ferrone CR, et al. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy[J]. JAMA Surg, 2019, 154:943-951. doi: 10.1001/jamasurg.2019.2272 |
| [74] | Verma V, Li JL, Lin C. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications[J]. Am J Clin Oncol, 2016, 39: 302-313. doi: 10.1097/COC.0000000000000278 |
| [75] | Roland CL, Katz MH, Tzeng CW, et al. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S1221-S1228. http://www.ncbi.nlm.nih.gov/pubmed/26350371 |
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad: